Sugammadex, a Promising Reversal Drug. A Review of Clinical Trials

Author(s): Ira Makri, Artemisia Papadima, Aimilia Lafioniati, Apostolos B. Pappas, Karanikas George, Koronakis E. Nikolaos, Chrysikos D. Ioannis, Seretis Charalambos, Lagoudianakis E.Emmanuel, Theodoros Xanthos, Lila Papadimitriou.

Journal Name: Reviews on Recent Clinical Trials

Volume 6 , Issue 3 , 2011

Become EABM
Become Reviewer

Abstract:

According to published data, sugammadex, rapidly reverses (2-5 min) shallow and profound NM block induced by rocuronium and vecuronium, without being connected with serious adverse events. It is accepted that in order to reverse shallow block, the suggested dose of sugammadex comes up to 2 mg/kg. Profound level of NM block demands 4 mg/kg in order to defy few responses at the post titanic count. Doses of sugammadex lower than 1 mg/kg may lead to rebound of rocuroniums effect. Higher doses of sugammadex (12 – 16 mg/g) are used in rescue reversal. In children and adolescents the 2 mg/kg dose is both effective and well tolerated, while, to date, data regarding infants are scarce. In patients with renal failure, 2 mg/kg of sugammadex resulted in a mean time to recovery of TOF ratio to 0.9 in 2 min, which was quicker than the time of reversal by acetylcholinesterase inhibitors. Investigations in cardiac patients undergoing noncardiac surgery suggest that 2 and 4 mg/kg of sugammadex are both safe and effective. Compared with neostigmine, sugammadex has no need to use muscarinic antagonists and therefore is not associated with variations in heart rate. Trials indicate that sugammadex acts faster than edrophonium and neostigmine. Sugammadex is a promising, well tolerated agent that enables fast reversal in different depths of NM block -shallow and profound- and in different patients ’ populations. After completion of trial probation and settlement of issues concerning estimated cost and cost impact, it is believed to play a leading part in future anesthesiology.

Keywords: Anesthesia, cyclodextrins, drugs, neuromuscular blocking agents, sugammadex, sugar molecules, neuromuscular blocking agents (NMBAs), Phase I Trials, Phase II Trials, Phase III Trials, gammacyclodextrin

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 6
ISSUE: 3
Year: 2011
Page: [250 - 255]
Pages: 6
DOI: 10.2174/157488711796575559
Price: $58

Article Metrics

PDF: 9